Jun 15, 2022 / 06:20PM GMT
Unidentified Analyst -
Great. Good morning, everyone. We'll get started. I'm very pleased to have Bradley Campbell, the President and COO of Amicus Therapeutics here with us. this morning, and I'll maybe open it up with a quick 30-second, 1-minute intro commentary.
Bradley L. Campbell - Amicus Therapeutics, Inc. - President, COO & Director
Sure, yes. First of all, thanks a lot to you for hosting and to Goldman for having us here. It's a great conference, and good to be together for the first time in a long time, it seems, which is great.
So just top line in Amicus. So we are very focused on, I think, 3 key priorities. First is to continue to grow Galafold, our core business for Fabry disease, confident we'll do $350 million to $365 million in sales this year, which will continue our strong double-digit growth that we continue to foresee going forward. Very focused on getting AT-GAA approved. We're -- I'm sure we'll talk a lot more about that, but we're excited to be approaching our PDUFA dates here in the United States with the BLA, in particular, in
Amicus Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers